Lv1
40 积分 2022-12-08 加入
Relationship between T90% and common comorbidities in patients with obstructive sleep apnea hypopnea syndrome
10天前
已完结
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
11天前
已完结
Wegovy weight loss pill gets UK approval
21天前
已关闭
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
1个月前
已完结
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
1个月前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
1个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
1个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
1个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
2个月前
已完结
皖公网安备34019202002308
